Xentria Unveils Xturnpoint to Accelerate Therapeutic Innovations and Expands Headquarters Xentria, Inc. launches Xturnpoint, a studio for early-stage therapeutic innovators, alongside a significant headquarters expansion in Chicago.

Xentria Unveils Xturnpoint to Accelerate Therapeutic Innovations and Expands Headquarters #Chicago #biotherapeutics #Xentria #Xturnpoint

Xentria's XTMAB16 Study Achieves Major Milestone in Pulmonary Sarcoidosis Treatment Research Xentria successfully completes enrollment in the XTMAB16 Study, focusing on pulmonary sarcoidosis treatment, advancing innovative therapies.

Xentria's XTMAB16 Study Achieves Major Milestone in Pulmonary Sarcoidosis Treatment Research #United_States #Chicago #Xentria #XTMAB16 #Sarcoidosis

Xentria Sets New Standard in Biosimilar Development in Global Markets Xentria, Inc. celebrates its milestone achievements in biosimilar development, expanding clinical trials in multiple countries to enhance patient access to affordable therapies.

Xentria Sets New Standard in Biosimilar Development in Global Markets #United_States #Chicago #healthcare #Biosimilars #Xentria

Xentria Partners with NYU for Innovative Cardiovascular Therapy Development Xentria, Inc. has announced an exclusive agreement with NYU to develop a groundbreaking cardiovascular therapeutic, aiming to revolutionize treatment options globally.

Xentria Partners with NYU for Innovative Cardiovascular Therapy Development #United_States #Chicago #Xentria #NYU #GL-12